| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 06/28/2001 | WO2001046184A1 3-thiazol-4-yl-pyprolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046172A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | WO2001046136A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001045742A1 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
| 06/28/2001 | WO2001045689A2 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 06/28/2001 | WO2000078765A3 CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |
| 06/28/2001 | WO2000066104A3 Ace-2 inhibiting compounds and methods of use thereof |
| 06/28/2001 | US20010005513 With water insoluble starch carrier; allows dry storage and lower doses of active ingredient |
| 06/28/2001 | CA2395520A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 06/28/2001 | CA2395202A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | CA2395113A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | CA2394789A1 Proteases |
| 06/28/2001 | CA2392787A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/27/2001 | EP1111050A2 Human procalcitonin, its production and use |
| 06/27/2001 | EP1109909A2 Grf analogs with increased biological potency |
| 06/27/2001 | EP1109907A1 Human cell junction pdz protein |
| 06/27/2001 | EP1109824A1 Novel bag proteins and nucleic acid molecules encoding them |
| 06/27/2001 | EP1109785A2 Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation |
| 06/27/2001 | EP1109572A2 Neuroprotection |
| 06/27/2001 | EP1109554A2 Pipecolic acid derivatives for vision and memory disorders |
| 06/27/2001 | EP1109534A1 Quick release pharmaceutical compositions of drug substances |
| 06/27/2001 | EP0797564B1 Lignans, a process for their production and pharmaceutical compositions and uses thereof |
| 06/27/2001 | CN1301271A Methods for identifying inducers and inhibitors of propteolytic antibodies, compositions and their uses |
| 06/27/2001 | CN1301146A Topical hormonal composition with systemic effect |
| 06/27/2001 | CN1067687C Polymorphic foams of growth hormone secretagogue |
| 06/27/2001 | CN1067550C Calcium receptor active molecules |
| 06/26/2001 | US6251924 Pharmaceutical composition |
| 06/26/2001 | US6251902 Dipeptide derivatives as growth hormone secretagogues |
| 06/24/2001 | CA2329516A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 06/21/2001 | WO2001044448A2 Human oxidoreductase proteins |
| 06/21/2001 | WO2001044273A2 Receptor-selective somatostatin analogs |
| 06/21/2001 | WO2001044268A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 06/21/2001 | WO2001044267A1 11-β-PHENYLESTRADIENE DERIVATIVES WITH FLUOROALKYL GROUPS IN THE AROMATIC SIDE CHAIN, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS |
| 06/21/2001 | WO2001044260A2 Novel purines |
| 06/21/2001 | WO2001044243A2 Novel heteroaryl-diazabicycloalkanes |
| 06/21/2001 | WO2001044191A1 4-aminopiperidine derivatives and their use as medicine |
| 06/21/2001 | WO2001043773A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 06/21/2001 | WO2001043763A1 Betaglycan as an inhibin receptor and uses thereof |
| 06/21/2001 | WO2001043762A2 Polypeptide compositions with improved stability |
| 06/21/2001 | WO2001043749A2 Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
| 06/21/2001 | WO2001043724A1 Microcapsules for sustained release of drugs |
| 06/21/2001 | WO2001043720A1 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof |
| 06/21/2001 | WO2001043540A2 Methods for producing transgenic animals |
| 06/21/2001 | WO2001016136A3 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 06/21/2001 | WO2001014535A3 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc to GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 06/21/2001 | WO2000078972A8 Regulation with binding cassette transporter protein abc1 |
| 06/21/2001 | DE19959697A1 14,15-Cyclopropanosteroide der 19-Norandrostan-Reihe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen 14,15-Cyclopropanosteroide the 19-norandrostane series, process for their preparation and pharmaceutical compositions containing them |
| 06/21/2001 | DE19959696A1 Ungesättigte 14,15-Cyclopropano-Androstane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen Unsaturated 14,15-cyclopropano-androstanes, to processes for their preparation containing these compounds and pharmaceutical compositions |
| 06/21/2001 | CA2394646A1 Novel purines |
| 06/21/2001 | CA2394600A1 Methods for producing transgenic animals |
| 06/21/2001 | CA2394576A1 Betaglycan as an inhibin receptor and uses thereof |
| 06/21/2001 | CA2394416A1 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof |
| 06/21/2001 | CA2394213A1 Polypeptide compositions with improved stability |
| 06/21/2001 | CA2394160A1 Human oxidoreductase proteins |
| 06/21/2001 | CA2391957A1 Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
| 06/20/2001 | EP1108013A2 Genes associated with neurotransmitter processing |
| 06/20/2001 | EP1107775A1 Composition containing pyrrolizidine-alkaloid-free petasites |
| 06/20/2001 | EP1107743A1 Stable spray-dried protein formulations |
| 06/20/2001 | EP1107738A1 Novel pharmaceutical salt form |
| 06/20/2001 | EP1107702A1 Ultrasonic enhancement of drug injection |
| 06/20/2001 | EP0920438B1 N6 heterocyclic substituted adenosine derivatives |
| 06/20/2001 | EP0686037B1 Hormone replacement therapy |
| 06/20/2001 | CN1300291A Modulators of protein tyrosine phosphatases |
| 06/20/2001 | CN1300281A Compounds with growth hormone releasing properties |
| 06/20/2001 | CN1300277A Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
| 06/20/2001 | CN1300218A Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 06/19/2001 | US6248781 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
| 06/19/2001 | US6248780 Therapy for breast cancer |
| 06/19/2001 | US6248753 Bicyclic compounds |
| 06/19/2001 | US6248717 Tartrate salt of a substituted dipeptide as growth hormone secretagogue |
| 06/19/2001 | US6248594 Kinesin-like motor protein |
| 06/19/2001 | US6248363 Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents |
| 06/19/2001 | US6248335 Ph control |
| 06/19/2001 | US6248326 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor |
| 06/19/2001 | US6248305 Boron heterocycle steroid mimics and associated pharmaceutical compositions and methods of use |
| 06/14/2001 | WO2001042449A2 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042275A1 Unsaturated 14,15-cyclopropane-androstanes, a method for their production and pharmaceutical compositions containing these compounds |
| 06/14/2001 | WO2001042274A1 14,15-cyclopropanosteroids of the 19-norandrostane series, method for producing said compounds and pharmaceutical preparation containing said compounds |
| 06/14/2001 | WO2001042265A2 N6 heterocyclic 8-modified adenosine derivatives |
| 06/14/2001 | WO2001042237A1 3-methyl-chromane or thiochromane derivatives |
| 06/14/2001 | WO2001042236A1 Metal salts of 3-methyl-chromane or thiochromane derivatives |
| 06/14/2001 | WO2001042235A1 3-ethyl-, 3-propyl- or 3-butyl-chroman and -thiochroman derivatives |
| 06/14/2001 | WO2001042234A1 3-methyl-chroman and -thiochroman derivatives |
| 06/14/2001 | WO2001042233A1 Optically active chroman and thiochroman derivatives |
| 06/14/2001 | WO2001042216A2 Caspase inhibitors and uses thereof |
| 06/14/2001 | WO2001042186A1 Compound having hydroxycarbonyl-halogenoalkyl side chain |
| 06/14/2001 | WO2001042181A1 Benzyl tetralins, formulations and uses thereof |
| 06/14/2001 | WO2001041778A1 Melanin synthesis inhibition compound and composition containing the same |
| 06/14/2001 | WO2001017989A3 Heteroaryloxypropanolamines as beta3-adrenergic receptor agonists |
| 06/14/2001 | WO2001016133A3 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/14/2001 | CA2733434A1 Caspase inhibitors and uses thereof |
| 06/14/2001 | CA2394636A1 Compound having hydroxycarbonyl-halogenoalkyl side chains |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2383001A1 Methods for introducing genes into mammalian subjects |
| 06/13/2001 | EP1106179A2 Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
| 06/13/2001 | EP1105501A2 Tpl-2/cot kinase and methods of use |
| 06/13/2001 | EP1105478A1 Extracellular adhesive proteins, exadh1 and exadh2 |
| 06/13/2001 | EP1105409A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 06/13/2001 | EP1105408A1 Congugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agents |